Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-05-13Clinical Trial Update: Plaque Psoriasis Efficacy and Safety With Secukinumab [Phase 3]
Phase 3 trial results for secukinumab in plaque psoriasis have been completed with posted results in 2019.
-
CLINICAL_TRIALS trial_result · 2019-05-08Clinical Trial Update: Sequential Treatment of Psoriasis With Integrated Traditional Chinese and Western Medicine [Phase 2]
Phase 2 trial update exploring sequential treatment of plaque psoriasis using an integrated Traditional Chinese and Western medicine approac…
-
CLINICAL_TRIALS trial_result · 2019-05-03Clinical Trial Update: Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy [Phase 2]
Phase 2 efficacy study of CDP870 in chronic plaque psoriasis completed with posted results.
-
FDA approval · 2019-04-25FDA Approved: DUOBRII — Original Application (Bausch Health US, LLC)
FDA approved Duobrí (halobetasol propionate and tazarotene) as a new fixed-dose topical combination for the treatment of plaque psoriasis in…
-
FDA approval · 2019-04-23FDA Approved: SKYRIZI — Original Application (AbbVie Inc.)
FDA approved SKYRIZI (risankizumab-rzaa) from AbbVie as the original approval for adults with moderate to severe plaque psoriasis. Risankizu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-04-23Clinical Trial Update: A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) [Phase 3]
Phase 3 trial update evaluating secukinumab 300 mg in adults with moderate-to-severe plaque psoriasis; completed with posted results in 2019…
-
CLINICAL_TRIALS withdrawal · 2019-04-18Clinical Trial Update: Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients [Phase 4]
Clinical trial NCT03146247 evaluating itch pathogenesis in response to apremilast in plaque psoriasis was withdrawn.
-
CLINICAL_TRIALS trial_result · 2019-03-29Clinical Trial Update: Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis [Phase 2]
Phase 2 clinical trial evaluating safety and efficacy of PF-06700841 in moderate-to-severe plaque psoriasis has completed with posted result…
-
CLINICAL_TRIALS trial_result · 2019-03-28Clinical Trial Update: Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy [Phase 4]
Phase 4 clinical trial update evaluating apremilast in patients with plaque psoriasis who are dissatisfied with stable maintenance topical t…
-
CLINICAL_TRIALS trial_result · 2019-03-13Clinical Trial Update: Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis [Phase 4]
Phase 4 trial assessing the efficacy and safety of Enstilar Foam in combination with Apremilast (Otezla) for moderate plaque psoriasis; stud…
-
CLINICAL_TRIALS trial_result · 2019-03-12Clinical Trial Update: A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis [Phase 2]
Phase 2 trial evaluating escalating oral doses of itacitinib in patients with plaque psoriasis; study completed.
-
CLINICAL_TRIALS trial_result · 2019-02-21Clinical Trial Update: Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis [Phase 2]
A Phase 2 trial comparing HAT1 to calcipotriol in mild-to-moderate chronic plaque psoriasis has completed and reports on efficacy and safety…
-
CLINICAL_TRIALS trial_result · 2019-02-19Clinical Trial Update: MSB11022 in Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 trial update for MSB11022 in moderate to severe chronic plaque psoriasis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis [Phase 3]
A Phase 3 trial comparing guselkumab to fumaric acid esters in moderate to severe plaque psoriasis has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test [Phase 1]
Phase 1 trial evaluating the potency of SOR007 Ointment for plaque psoriasis has completed.
-
FDA approval · 2019-02-15FDA Approved: CLOBETASOL PROPIONATE — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approves Glenmark's generic clobetasol propionate topical product under an Original Application (ANDA).
-
FDA approval · 2019-02-13FDA Approved: FLUOCINOLONE ACETONIDE TOPICAL SOLUTION USP, 0.01% — Original Application (Encube Ethicals, Inc.)
FDA approves Encube Ethicals' generic fluocinonide acetonide topical solution 0.01% (Original Application) for inflammatory and pruritic cor…
-
CLINICAL_TRIALS trial_result · 2019-02-08Clinical Trial Update: Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 trial comparing BI 695501, a biosimilar, with Humira in moderate to severe chronic plaque psoriasis assessed for efficacy, safety, a…
-
FDA label_change · 2019-01-29FDA Approved: TREMFYA — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for TREMFYA (guselkumab) by Janssen Biotech, Inc., resulting in changes to the labeling.
-
CLINICAL_TRIALS trial_result · 2019-01-28Clinical Trial Update: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
This clinical trial update reports on patient adherence attitudes toward scheduled adalimumab maintenance therapy across multiple inflammato…
-
CLINICAL_TRIALS trial_result · 2019-01-28Clinical Trial Update: Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis [Phase 4]
Phase 4 trial evaluating apremilast 30 mg twice daily in combination with narrowband UVB for plaque psoriasis; results have been posted.
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients [Phase 2]
Phase 2 study of oral MP1032 in psoriasis patients has completed and results have been posted. The trial evaluated safety and efficacy in pl…
-
CLINICAL_TRIALS trial_result · 2019-01-22Clinical Trial Update: Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis [Phase 1]
A Phase 1 study evaluating the safety and tolerability of Calcipotriene foam 0.005% in pediatric patients with mild-to-moderate plaque psori…
-
CLINICAL_TRIALS withdrawal · 2019-01-17Clinical Trial Update: A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Plaque Psoriasis in Adults [Phase 2]
A Phase 2 trial evaluating a botanical drug containing East Indian Sandalwood Oil for plaque psoriasis in adults has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-12-27Clinical Trial Update: A Long Term Safety Extension Study (CHS-0214-05) [Phase 3]
Phase 3 long-term safety extension study for a therapy in rheumatoid arthritis and plaque psoriasis has completed with results posted in 201…